RT @RaElias_MD: @NicoleKuderer We published a meta-analysis in @sitcancer journal showing no difference in efficacy based on an age https:…
RT @RaElias_MD: @NicoleKuderer We published a meta-analysis in @sitcancer journal showing no difference in efficacy based on an age https:…
@NicoleKuderer We published a meta-analysis in @sitcancer journal showing no difference in efficacy based on an age https://t.co/vG9L3nVeCh
RT @RaElias_MD: Here's the link to the full paper : https://t.co/c7qC1Uaj21 https://t.co/1EsRavsGlI
RT @RaElias_MD: Here's the link to the full paper : https://t.co/c7qC1Uaj21 https://t.co/1EsRavsGlI
Here's the link to the full paper : https://t.co/c7qC1Uaj21 https://t.co/1EsRavsGlI
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/NS…
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/NS…
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/NS…
#JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/NSE3SrLorp
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. #cancer #immunotherapy https://t.co/dmBz2BgxiX
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/F1…
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/F1…
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/F1…
RT @sitcancer: #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/F1…
#JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/F1eqCq9EmY
RT @OsamaRahma2: Immune checkpoint inhibitors are as effective in older population. One of very few reports in Geri-immune-Oncology @RaElia…
There's been an ongoing debate of ICB efficacy in young vs old (preclinical). Interestingly, a new study suggest that ICBs are in fact equally effective in younger and older patients. https://t.co/esk4IV5SXJ #scienceitup
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. https://t.co/DdvBirGArY
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @sitcancer: New #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.c…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
RT @RaElias_MD: Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥…
Interesting, important https://t.co/i2j3j4DsOh
RT @OsamaRahma2: Immune checkpoint inhibitors are as effective in older population. One of very few reports in Geri-immune-Oncology @RaElia…
RT @OsamaRahma2: Immune checkpoint inhibitors are as effective in older population. One of very few reports in Geri-immune-Oncology @RaElia…
Immune checkpoint inhibitors are as effective in older population. One of very few reports in Geri-immune-Oncology @RaElias_MD @DanaFarber https://t.co/U8u2hLPfSY
Very excited about our @sitcancer #JITC paper: meta-analysis evaluating efficacy of PD-1/PD-L1 antibodies in adults < vs ≥ 65 years. Lucky to have the mentorship of @OsamaRahma2 and to collaborate with some of the best #ImmunoOnc @DanaFarber https:/
RT @sitcancer: New #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.c…
RT @sitcancer: New #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.c…
Age and PD-1 or PDL-1 blockade: large analysis shows comparable efficacy https://t.co/bVz2PRQty0
New #JITC Research: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis https://t.co/Sm4zoVz8II https://t.co/DvQ5YwK3lA